Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria

NCT06736262 is registered in ClinicalTrials.gov with Jasper Therapeutics, Inc. as lead sponsor.

NCT NCT06736262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria
Lead sponsor
Jasper Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 26, 2024
Completion date
July 21, 2026
Enrollment
67 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria chronic